Sugi Predict

Sugi Predict / Compounds / SCHEMBL1010499

SCHEMBL1010499

SCHEMBL1010499

NC(=O)c1cnc(N2CC3C(C2)C3NCc2ccc3cc(F)ccc3n2)nc1

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 20/20 0.81
▸ HDAC2 Q92769 20/20 0.81
▸ HDAC3 O15379 19/20 0.81
▸ HDAC4 P56524 19/20 0.81
▸ HDAC7 Q8WUI4 19/20 0.81
▸ HDAC10 Q969S8 19/20 0.81
▸ HDAC11 Q96DB2 19/20 0.81
▸ HDAC8 Q9BY41 19/20 0.81
▸ HDAC6 Q9UBN7 19/20 0.81
▸ HDAC9 Q9UKV0 19/20 0.81
▸ HDAC5 Q9UQL6 19/20 0.81
▸ CYP3A4 P08684 1/20 0.81
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nanatinostat SCHEMBL22712412 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL22712419 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL29602260 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL25612092 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL1014672 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL29453926 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
Nanatinostat SCHEMBL22712415 0.90 HDAC3 (1.00) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL23510865 0.88 HDAC3 (0.81) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL30025918 0.87 HDAC1 (0.68) HDAC1HDAC2HDAC3HDAC4HDAC7
SCHEMBL23460854 0.87 HDAC1 (0.68) HDAC1HDAC2HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12012396-B2 HDAC inhibitor solid state forms Viracta Subsidiary, Inc. (CA) 2024-06-18 — — US claimed
US-20240166628-A1 HDAC INHIBITOR SOLID STATE FORMS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2024-05-23 — — US claimed
US-20240101530-A1 HDAC INHIBITOR SOLID STATE FORMS Viracta Subsidiary, Inc. 2024-03-28 — — US claimed
US-20230382888-A1 HDAC INHIBITOR SOLID STATE FORMS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-11-30 — — US claimed
US-11780822-B2 HDAC inhibitor solid state forms Viracta Subsidiary, Inc. (US) 2023-10-10 — — US claimed
US-11760748-B2 HDAC inhibitor solid state forms Viracta Subsidiary, Inc. (US) 2023-09-19 — — US claimed
EP-4237409-A1 HDAC INHIBITOR SOLID STATE FORMS Viracta Subsidiary, Inc. (US) 2023-09-06 — — EP claimed
US-20230159499-A1 HDAC INHIBITOR SOLID STATE FORMS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-05-25 — — US claimed
US-20230159494-A1 HDAC INHIBITOR SOLID STATE FORMS Viracta Subsidiary, Inc. 2023-05-25 — — US claimed
US-20230023953-A1 HDAC INHIBITOR SOLID STATE FORMS Viracta Subsidiary, Inc. 2023-01-26 — — US claimed
WO-2022094122-A1 HDAC INHIBITOR SOLID STATE FORMS Viracta Subsidiary, Inc. (US) 2022-05-05 — — WO claimed
WO-2021113694-A1 HDAC INHIBITOR SOLID STATE FORMS VIRACTA THERAPEUTICS, INC. (US) 2021-06-10 — — WO claimed
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 — — US claimed
EP-1881977-B1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-01-05 — — EP claimed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 — — US claimed
EP-1881977-A1 HISTONE DEACETYLASE INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-30 — — EP claimed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 — — WO claimed
US-12012396-B2 HDAC inhibitor solid state forms Viracta Subsidiary, Inc. (CA) 2024-06-18 — — US disclosed
EP-1881977-A1 HISTONE DEACETYLASE INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-30 — — EP disclosed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159494-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC2, HDAC1, HDAC3 HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885
US-11760748-B2 HDAC inhibitor solid state forms HDAC1, HDAC2, HDAC5 HDAC1 1/4885HDAC2 2/4885HDAC3 5/4885
US-20240101530-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC2, HDAC1, HDAC3 HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885
US-20230382888-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC1, HDAC2, HDAC5 HDAC1 1/4885HDAC2 2/4885HDAC3 5/4885
US-20230023953-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC2, HDAC1, HDAC3 HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885
US-20230159499-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC1, HDAC2, HDAC5 HDAC1 1/4885HDAC2 2/4885HDAC3 5/4885
US-12012396-B2 HDAC inhibitor solid state forms HDAC1, HDAC2, HDAC5 HDAC1 1/4885HDAC2 2/4885HDAC3 5/4885
US-20240166628-A1 HDAC INHIBITOR SOLID STATE FORMS HDAC1, HDAC2, HDAC5 HDAC1 1/4885HDAC2 2/4885HDAC3 5/4885
US-11780822-B2 HDAC inhibitor solid state forms HDAC2, HDAC1, HDAC3 HDAC1 2/4885HDAC2 1/4885HDAC3 3/4885
US-20100152155-A1 Histone Deacetylase Inhibitors HDAC1, HDAC2, HDAC11 HDAC1 1/4885HDAC2 2/4885HDAC3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.